Inbio ventures

Pharmstandard International S.A. Represented by Inbio Ventures Participated in Growth Financing of TransMedics, Inc. from a Strong Investor Syndicate to Transform Organ Transplant Therapy

Moscow, Russia, May 26, 2016  – Pharmstandard International, S.A., has joined the $51.2 million growth equity financing round for TransMedics, Inc., a medical technology company dedicated to improving quality, assessing viability and increasing the utilization of donor organs for transplantation.

 

The financing was co-led by new global life science investors Loreda Investments, Pharmstandard International S.A. represented by Inbio Ventures, Millhouse Capital and included BioStar Ventures.  In addition, existing investors Abrams Capital, United Therapeutics, Flagship Ventures and KPCB participated in this financing.

 

“We are thankful and excited to be supported by a world-class syndicate of new and existing life science investors. This financing best positions TransMedics to capitalize on the significant market opportunity in front of us,” said Dr. Waleed Hassanein, President and CEO of TransMedics.

 

“We are delighted to be able to support the revolutionizing technology in organ transplant which has potential to replace cold storage with Organ Care System (OCS™) in multiple organ transpant practices. Despite the main investment focus of Pharmstandard International / Inbio which is aimed at pharmaceuticals, we are flexible enough to accommodate investment into medical care device space, while still striving to support development of best therapeutic options to help patients suffering from the diseases with yet unmet meecial needs,” said Dr. Andrey Petrov, Founder and CEO of Inbio Ventures.

 

TransMedics has developed the Organ Care System (OCS™), a revolutionary first-in-class technology and multi-organ platform with the potential to improve outcomes for transplant patients and to dramatically increase the number of transplantable organs worldwide. The OCS™ is the only fully portable technology that maintains donor organs in a near-physiologic state outside of the human body and addresses the current limitations of cold storage.  The OCS™ Heart and OCS™ Lung systems are CE Marked and used by leading transplant centers in Europe, Australia and Canada.  The OCS™ Heart, OCS™ Lung, and OCS™ Liver are currently in clinical trials in the United States. The results of the OCS™ Lung INSPIRE trial were recently presented at the 2016 annual meeting of The International Society for Heart and Lung Transplantation (ISHLT) in Washington, D.C.

 

About TransMedics, Inc.

TransMedics, Inc. is the world’s leader in portable ex-vivo warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation, and has developed technologies to improve organ quality, validate organ viability, and increase the utilization of transplant organs for the treatment of end-stage heart, lung, liver and kidney failure. For more information, please visit: www.transmedics.com

Contact:

TransMedics, Inc.

Stephen Gordon, CFO

sgordon@transmedics.com

Tel: +19785525071

www.transmedics.com

 

About Pharmstandard International S.A. / Inbio Ventures

Pharmstandard International S.A. – is a company with the main focus on venture investments in innovative drugs/therapies with strong potential both globally and in Russia. Pharmstandard International S.A. is a fully owned subsidiary of PJSC Pharmstandard (LSE:PHST) – Russia’s leading pharmaceutical producer. For more information, please visit: www.pharmstd.lu

Inbio Ventures JSC – is a management company representing Pharmstandard International S.A., and providing professional support in venture transactions. For more information, please visit: http://www.inbio-ventures.com/